| Literature DB >> 35140804 |
Ahmad El Askary1, Alaa Shafie1, Mazen Almehmadi1, Hatem H Allam2, Lamiaa K Elsayyad2, Asmaa F Hassan3, Bader B Althobaiti4, Mohamed Mansour Khalifa5,6, Tamer Saber7, Aisha H Alharthi1, Amal F Gharib1.
Abstract
BACKGROUND: Diabetes mellitus type 2 and vitamin D deficiency are both prevalent in the Saudi Arabia. Vitamin D deficiency treatment with supplements carries a risk of intoxication. AIM: The present study is aimed at elucidating the effect of exercise on modulation of metabolic status and vitamin D level in patients with type 2 diabetes mellitus (T2DM).Entities:
Mesh:
Substances:
Year: 2022 PMID: 35140804 PMCID: PMC8818417 DOI: 10.1155/2022/3059629
Source DB: PubMed Journal: Comput Math Methods Med ISSN: 1748-670X Impact factor: 2.238
The progression of moderate-intensity treadmill aerobic exercises (T-AE).
| Week | Intensity % | Time (min) |
|---|---|---|
| 1, 2 | 50% | 20 |
| 3, 4 | 55% | 25 |
| 5, 6 | 60% | 30 |
| 7, 8 | 65% | 35 |
| 9, 10 | 70% | 40 |
| 11, 12 | 70% | 40 |
Bonferroni pairwise comparisons for preintervention laboratory data between-subjects included in the study.
| Laboratory data | Diabetic study group ( | Diabetic control group ( |
|
|---|---|---|---|
| Previtamin D ng/ml | 19.53 ± 5.81 | 20.12 ± 6.51 | 0.617 |
| Pretotal cholesterol (mg/dl) | 263.62 ± 50.05 | 259.98 ± 44.21 | 0.687 |
| Pretriglycerides (mg/dl) | 352.45 ± 73.95 | 348.20 ± 46.20 | 0.718 |
| Pre-LDL-C (mg/dl) | 185.27 ± 42.01 | 179.35 ± 30.23 | 0.398 |
| Pre-HDL-C (mg/dl) | 32.27 ± 7.58 | 34.98 ± 10.49 | 0.123 |
| Prefasting glucose (mg/dl) | 272.76 ± 64.83 | 267.93 ± 52.62 | 0.668 |
| Pre-HbA1c (%) | 11.25 ± 2.46 | 10.84 ± 1.28 | 0.268 |
| Prefasting insulin ( | 20.02 ± 2.06 | 20.13 ± 2.15 | 0.786 |
| Pre-HOMA-IR | 9.38 ± 2.16 | 9.85 ± 2.12 | 0.250 |
Bonferroni pairwise comparisons for postintervention laboratory data (between-subjects).
| Laboratory data | Diabetic study group ( | Diabetic control group ( |
|
|---|---|---|---|
| Postvitamin D (ng/ml) | 24.97 ± 6.66 | 20.17 ± 6.64 | <0.001∗∗ |
| Posttriglycerides (mg/dl) | 162.05 ± 47.38 | 348.40 ± 45.73 | <0.001∗∗ |
| Post-LDL-C (mg/dl) | 144.67 ± 30.79 | 179.38 ± 29.66 | <0.001∗∗ |
| Post-HDL-C (mg/dl) | 39.16 ± 10.86 | 35.02 ± 10.55 | 0.045∗ |
| Postfasting glucose (mg/dl) | 169.49 ± 55.34 | 268.13 ± 52.57 | <0.001∗∗ |
| Post-HbA1c (%) | 7.54 ± 1.37 | 10.85 ± 1.35 | <0.001∗∗ |
| Postfasting insulin ( | 15.85 ± 2.03 | 20.15 ± 2.29 | <0.001∗∗ |
| Post-HOMA-IR | 5.49 ± 1.43 | 9.91 ± 2.20 | <0.001∗∗ |
∗ p value < 0.05 S; ∗∗p value < 0.001 HS.
Bonferroni pairwise comparisons for Laboratory data (within-subjects) in patients group.
| Laboratory data | Diabetic study group ( | Bonferroni | ||
|---|---|---|---|---|
| Preintervention | Postintervention | Mean diff. |
| |
| Vitamin D ng/ml | 19.53 ± 5.81 | 24.97 ± 6.66 | -5.436 | <0.001∗∗ |
| Total cholesterol (mg/dl) | 263.62 ± 50.05 | 227.87 ± 48.40 | 35.745 | 0.002∗ |
| Triglycerides (mg/dl) | 352.45 ± 73.95 | 162.05 ± 47.38 | 190.400 | <0.001∗∗ |
| LDL (mg/dl) | 185.27 ± 42.01 | 144.67 ± 30.79 | 40.600 | <0.001∗∗ |
| HDL (mg/dl) | 32.27 ± 7.58 | 39.16 ± 10.86 | -6.891 | 0.002∗ |
| Fasting glucose (mg/dl) | 272.76 ± 64.83 | 169.49 ± 55.34 | 103.273 | <0.001∗∗ |
| HbA1c (%) | 11.25 ± 2.46 | 7.54 ± 1.37 | 3.713 | <0.001∗∗ |
| Fasting insulin ( | 20.02 ± 2.06 | 15.85 ± 2.03 | 4.164 | <0.001 ∗∗ |
| HOMA-IR | 9.38 ± 2.16 | 5.49 ± 1.43 | 3.891 | <0.001 ∗∗ |
∗ p value < 0.05 S; ∗∗p value < 0.001 HS.
| Multivariate test | |||||
|---|---|---|---|---|---|
| Value |
| Hypothesis df | Error df | Sig | |
| Wilks' lambda | 0.968 | 1.781 | 2.000 | 107.000 | 0.173 |
| Bonferroni pairwise comparisons | ||||
|---|---|---|---|---|
| Demographic variables | Diabetic study group | Diabetic control group | Mean diff. diabetic study–diabetic control | Significance |
| Age (year) | 47.95 ± 5.08 | 46.47 ± 5.05 | 1.48 | 0.130 |
| Sex | ||||
| Female | 26 | 28 | 1.23 | 0.703 |
| Male | 29 | 27 | ||
| BMI percentile | 28.31 ± 3.35 | 27.65 ± 3.47 | 0.66 | 0.316 |